OOIR: Observatory of International Research

Papers

(The median citation count of Journal of Pharmacokinetics and Pharmacodynamics is 2. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)

Article	Citations
Application of different approaches to generate virtual patient populations for the quantitative systems pharmacology model of erythropoiesis	56
Population pharmacokinetic and pharmacodynamic model of propofol externally validated in Korean elderly subjects	29
Translational physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies	24
Advancing inclusive healthcare through PBPK modelling: predicting the impact of CYP genotypes and enzyme ontogenies on infant exposures of venlafaxine and its active metabolite O-desmethylvenlafaxine	23
Learning pharmacometric covariate model structures with symbolic regression networks	21
Achieving big with small: quantitative clinical pharmacology tools for drug development in pediatric rare diseases	20
Convolution-based approach for modeling the paliperidone extended release and Long-Acting Injectable (LAI) PK of once-, and three-monthly products administration and for optimizing the development of	19
ADPO: automatic-differentiation-assisted parametric optimization	15
Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	15
Correction: Model-based comparison of subcutaneous versus sublingual apomorphine administration in the treatment of motor fluctuations in Parkinson’s disease	15
Semi-mechanistic modeling of resistance development to β-lactam and β-lactamase-inhibitor combinations	14
Translational population target binding model for the anti-FcRn fragment antibody efgartigimod	13
Model-informed approach to estimate treatment effect in placebo-controlled clinical trials using an artificial intelligence-based propensity weighting methodology to account for non-specific responses	13
Current practices for QSP model assessment: an IQ consortium survey	13
Comparison of the power and type 1 error of total score models for drug effect detection in clinical trials	12
Mixed effect estimation in deep compartment models: Variational methods outperform first-order approximations	12
Imputation of missing clock times – application to procalcitonin concentration time course after birth	11
Generative models for synthetic data generation: application to pharmacokinetic/pharmacodynamic data	10
Mechanistic inference of the metabolic rates underlying $$^{13}$$C breath test curves	10
Population pharmacokinetics of the dual endothelin receptor antagonist aprocitentan in subjects with or without essential or resistant hypertension	10
Oral docetaxel plus encequidar – A pharmacokinetic model and evaluation against IV docetaxel	10
Training the next generation of pharmacometric modelers: a multisector perspective	10
Latent variable indirect response modeling of clinical efficacy endpoints with combination therapy: application to guselkumab and golimumab in patients with ulcerative colitis	10
Population pharmacokinetics and pharmacodynamics of efmarodocokin alfa (IL-22Fc)	10
Informatics for toxicokinetics	10

Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms	10
Expansion of platform physiologically-based pharmacokinetic model for monoclonal antibodies towards different preclinical species: cats, sheep, and dogs	10
Translational pharmacokinetic and pharmacodynamic modelling of the anti-ADAMTS-5 NANOBODY® (M6495) using the neo-epitope ARGS as a biomarker	9
Maximum a posteriori Bayesian methods out-perform non-compartmental analysis for busulfan precision dosing	9
Scoping review of the role of pharmacometrics in model-informed drug development	9
A translational physiologically-based pharmacokinetic model for MMAE-based antibody-drug conjugates	8
Exploring Inductive Linearization for simulation and estimation with an application to the Michaelis–Menten model	8
A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis	8
Longitudinal modeling of efficacy response in patients with lupus nephritis receiving belimumab	8
Application of model-informed drug development (MIDD) for dose selection in regulatory submissions for drug approval in Japan	8
Thanks to our Reviewers of 2022!	8
Correction to: Characterization of exposure–Clinical Dementia Rating–Sum of Boxes relationship in subjects with early Alzheimer’s disease from the aducanumab Phase 3 trials	7
A quantitative systems pharmacology model of plasma kallikrein-kinin system dysregulation in hereditary angioedema	7
Stochastic pharmacodynamics of a heterogeneous tumour-cell population	7
PBPK model for antibody disposition in mouse brain: validation using large-pore microdialysis data	7
Leveraging large language models in pharmacometrics: evaluation of NONMEM output interpretation and simulation capabilities	7
Advancing cancer drug development with mechanistic mathematical modeling: bridging the gap between theory and practice	7
Correction to: R-praziquantel integrated population pharmacokinetics in preschool- and school-aged African children infected with Schistosoma mansoni and S. haematobium and Lao adults infected with Op	7
Five multivariate Duchenne muscular dystrophy progression models bridging six-minute walk distance and MRI relaxometry of leg muscles	7
APOE4 genotypes and the trajectory of biomarkers, neuroimaging, and cognitive measures in Alzheimer’s Disease: A mixed-effects disease progression model	6
Population pharmacokinetic/pharmacodynamic modeling of nifekalant injection with varies dosing plan in Chinese volunteers: a randomized, blind, placebo-controlled study	6
A quantitative modeling framework to understand the physiology of the hypothalamic-pituitary-adrenal axis and interaction with cortisol replacement therapy	6
An automated pipeline to generate initial estimates for population Pharmacokinetic base models	6
Characterization of CAR-T cellular kinetics and efficacy in solid tumor patients with and without prior lymphodepletion chemotherapy using a PBPK-PD model	6
ChatGPT and Gemini large language models for pharmacometrics with NONMEM: comment	6
The impact of misspecified covariate models on inclusion and omission bias when using fixed effects and full random effects models	6
Sampling from covariate distribution may not always be necessary in PK/PD simulations: illustrative examples with antibiotics	6
Application of machine learning based methods in exposure–response analysis	6
Computing optimal drug dosing with OptiDose: implementation in NONMEM	5
JPKPD October Special Issue - Commentary	5
Physiologically-based pharmacokinetic modeling to predict drug-drug interaction of enzalutamide with combined P-gp and CYP3A substrates	5
An exploratory analysis of the performance of methylphenidate regimens based on a PKPD model of dopamine and norepinephrine transporter occupancy	5
A physiologically-based quantitative systems pharmacology model for mechanistic understanding of the response to alogliptin and its application in patients with renal impairment	5
A quantitative systems pharmacology model of plasma potassium regulation by the kidney and aldosterone	5
Correction to: Classical structural identifiability methodology applied to low-dimensional dynamic systems in receptor theory	5
Subgroup identification-based model selection to improve the predictive performance of individualized dosing	5
Identification and characterization of virtual sub-populations through phenotype-guided filtering. The challenging case of nonidentifiable models in the context of therapeutic evaluation	5
A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor	5
Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations	5
Knowledge dissemination and central indexing of resources in pharmacometrics: an ISOP education working group initiative	4
Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies	4
A note on phase I interleaved versus parallel group ascending dose designs for concentration-QTc analyses	4
In memory of Dr. Thomas M. Ludden: a pioneer in pharmacometrics, a mentor to many, and a legacy of compassionate science	4
Editor’s note on the themed issue: integration of machine learning and quantitative systems pharmacology	4
How drug onset rate and duration of action affect drug forgiveness	4
On inductive biases for the robust and interpretable prediction of drug concentrations using deep compartment models	4
External control arms for rare diseases: building a body of supporting evidence	4
Special issue: Model-informed drug development in rare diseases: connecting the dots in an information rich ecosystem	4
Do P-glycoprotein-mediated drug-drug interactions at the blood-brain barrier impact morphine brain distribution?	4
Thanks to our reviewers 2021!	4

A population pharmacokinetics model of balovaptan to support dose selection in adult and pediatric populations	3
Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma	3
Aggregate data modelling: A fast implementation for fitting pharmacometrics models to summary-level data in R	3
Challenges, approaches and enablers: effectively triangulating towards dose selection in pediatric rare diseases	3
Mechanistic incorporation of FcRn binding in plasma and endosomes in a whole body PBPK model for large molecules	3
No QT interval prolongation effect of sepiapterin: a concentration-QTc analysis of pooled data from phase 1 and phase 3 studies in healthy volunteers and patients with phenylketonuria	3
Exposure-safety Markov modeling of ocular adverse events in patient populations treated with tisotumab vedotin	3
Explaining in-vitro to in-vivo efficacy correlations in oncology pre-clinical development via a semi-mechanistic mathematical model	3
Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+ approach	3
Correction: Oral docetaxel plus encequidar – a pharmacokinetic model and evaluation against IV docetaxel	3
Understanding virtual patients efficiently and rigorously by combining machine learning with dynamical modelling	3
Empirical bayes approach for dynamic bayesian borrowing for clinical trials in rare diseases	3
Generation and application of avatars in pharmacometric modelling	3
Note on importance of correct stoichiometric assumptions for modeling of monoclonal antibodies	3
An industry perspective on current QSP trends in drug development	3
Should patients skip late doses of medication? A pharmacokinetic perspective	3
The future of rare disease drug development: the rare disease cures accelerator data analytics platform (RDCA-DAP)	2
Characterization of anti-drug antibody dynamics using a bivariate mixed hidden-markov model by nonlinear-mixed effects approach	2
A minimal physiologically based pharmacokinetic model to study the combined effect of antibody size, charge, and binding affinity to FcRn/antigen on antibody pharmacokinetics	2
Time Scale Calculus: a new approach to multi-dose pharmacokinetic modeling	2
Interoccasion variability in population pharmacokinetic models: identifiability, influence, interdependencies and derived study design recommendations	2
Physiologically-based pharmacokinetic model for predicting drug-drug interactions perpetrated by posaconazole in healthy subjects with normal weight and obesity: Concomitant use and washout	2
Correction to: Training the next generation of pharmacometric modelers: a multisector perspective	2
Computing optimal drug dosing regarding efficacy and safety: the enhanced OptiDose method in NONMEM	2
Towards a translational physiologically-based pharmacokinetic (PBPK) model for receptor-mediated transcytosis of anti-transferrin receptor monoclonal antibodies in the central nervous system	2
A next generation mathematical model for the in vitro to clinical translation of T-cell engagers	2
A quantitative systems pharmacology model for simulating OFF-Time in augmentation trials for Parkinson’s disease: application to preladenant	2
Towards a comprehensive assessment of QSP models: what would it take?	2
A comprehensive regulatory and industry review of modeling and simulation practices in oncology clinical drug development	2
International society of Pharmacometrics Mentorship Program (IMP): feedback survey from the first cohort of mentor-mentee pairs	2
Population pharmacokinetic analyses of pozelimab in patients with CD55-deficient protein-losing enteropathy (CHAPLE disease)	2
Correction: External control arms for rare diseases: building a body of supporting evidence	2
From data to QSP models: a pipeline for using Boolean networks for hypothesis inference and dynamic model building	2
Rare oncology therapeutics: review of clinical pharmacology package of drug approvals (2019–2023) by US FDA, best practices and recommendations	2